Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 7055
Gene Symbol: THAS
THAS
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE To assess whether regorafenib and TAS-102 treatments are associated with a change in Skeletal Muscle Area (SMA) as well as to compare Skeletal Muscle Mass (SMM) loss levels between regorafenib and TAS-102 treatments and prognostic significance in the patients with metastatic colorectal cancer (mCRC). 31786894

2020

Entrez Id: 7055
Gene Symbol: THAS
THAS
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Direct randomized comparisons of regorafenib, TAS-102, and fruquintinib for treating metastatic colorectal cancer (mCRC) are lacking. 31848739

2020

Entrez Id: 7055
Gene Symbol: THAS
THAS
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE We searched different databases for randomized controlled trials evaluating TAS-102 or regorafenib in patients with refractory mCRC who failed prior oxaliplatin, irinotecan, and fluoropyrimidine. 31164455

2019

Entrez Id: 7055
Gene Symbol: THAS
THAS
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Treatments in this setting can include regorafenib (an oral multikinase inhibitor), trifluridine/tipiracil hydrochloride (TAS-102), antibodies that target epidermal growth factor receptor for patients with RAS wild-type tumors (if no prior exposure), and, where approved, anti-programmed cell death protein 1 inhibitors for patients with microsatellite instability-high mCRC. 30598357

2019

Entrez Id: 7055
Gene Symbol: THAS
THAS
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE We retrospectively analyzed data from Japanese patients with refractory mCRC who received TAS-102 (35 mg/m<sup>2</sup>, twice a day) with (T-B group) or without Bmab (TAS-102 monotherapy; T group) between July 2014 and December 2018. 31748337

2019

Entrez Id: 7055
Gene Symbol: THAS
THAS
Secondary malignant neoplasm of colon and/or rectum
0.100 GeneticVariation BEFREE Disease progression, drug toxicity, and survival rates were based on the CheckMate 142, study of TAS-102 in patients with metastatic colorectal cancer refractory to standard chemotherapies (RECOURSE), and Cancer and Leukemia Group B/Southwest Oncology Group 80405 trials. 30343509

2019

Entrez Id: 7055
Gene Symbol: THAS
THAS
Secondary malignant neoplasm of colon and/or rectum
0.100 GeneticVariation BEFREE Trifluridine (FTD), a tri-fluorinated thymidine analogue, is a key component of the oral antitumor drug FTD/TPI (also known as TAS-102), which is used to treat refractory metastatic colorectal cancer. 31138881

2019

Entrez Id: 7055
Gene Symbol: THAS
THAS
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Regorafenib and TAS-102 are standard salvage-line treatment options for patients with chemorefractory metastatic colorectal cancer (mCRC). 30554226

2019

Entrez Id: 7055
Gene Symbol: THAS
THAS
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE The pretreatment NLR is a prognostic biomarker for patients with mCRC who receive TAS-102 treatment. 31366528

2019

Entrez Id: 7055
Gene Symbol: THAS
THAS
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Regorafenib Is Associated With Increased Skeletal Muscle Loss Compared to TAS-102 in Metastatic Colorectal Cancer. 31060856

2019

Entrez Id: 7055
Gene Symbol: THAS
THAS
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE TAS-102 (FTD/TPI) is a new oral anti-tumour agent composed of a nucleoside analogue, trifluridine, and a thymidine phosphorylase inhibitor, tipiracil, indicated for patients with mCRC who are refractory to standard therapies. 31002008

2019

Entrez Id: 7055
Gene Symbol: THAS
THAS
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Trifluridine/Tipiracil (TAS-102) for refractory metastatic colorectal cancer in clinical practice: a feasible alternative for patients with good performance status. 31209792

2019

Entrez Id: 7055
Gene Symbol: THAS
THAS
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE To investigate treatment patterns and outcomes of metastatic colorectal cancer (mCRC) patients beyond second progression (PD2) since regorafenib and TAS-102 became available in Hong Kong. 30887726

2019

Entrez Id: 7055
Gene Symbol: THAS
THAS
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Improving the cost-efficacy ratio of TAS-102 in metastatic colorectal cancer is needed to spare useless toxicities in a definitely palliative setting. 29739893

2018

Entrez Id: 7055
Gene Symbol: THAS
THAS
Secondary malignant neoplasm of colon and/or rectum
0.100 GeneticVariation BEFREE A total of 550 patients with mCRC who were registered in the REGOTAS study (Regorafenib versus TAS-102 as Salvage-line in patients with colorectal cancer refractory to standard chemotherapies: a multicenter observational study, UMIN 000020416) and treated with trifluridine/tipiracil (TFTD) or regorafenib as a later-line therapy were retrospectively stratified according to the modified Glasgow Prognostic Score (mGPS), which divided patients into mGPS 0 to 2 by serum albumin and C-reactive protein, and compared. 30149986

2018

Entrez Id: 7055
Gene Symbol: THAS
THAS
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Regorafenib and trifluridine/tipiracil (TAS-102) are novel antitumor agents for patients with refractory metastatic colorectal cancer. 30344762

2018

Entrez Id: 7055
Gene Symbol: THAS
THAS
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE TAS-102 may be suitable as third-line chemotherapy for patients with mCRC. 29599371

2018

Entrez Id: 7055
Gene Symbol: THAS
THAS
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer. 29274618

2018

Entrez Id: 7055
Gene Symbol: THAS
THAS
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE A Comparison of Regorafenib and TAS-102 for Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis. 29174481

2018

Entrez Id: 7055
Gene Symbol: THAS
THAS
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Cost-effectiveness Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer in the United States. 30228027

2018

Entrez Id: 7055
Gene Symbol: THAS
THAS
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE This meta-analysis is designed to assess the efficacy and safety of TAS-102 in patients with mCRC. 30214286

2018

Entrez Id: 7055
Gene Symbol: THAS
THAS
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study. 29215955

2018

Entrez Id: 7055
Gene Symbol: THAS
THAS
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE Trifluridine/tipiracil (TAS-102, Lonsurf®), a novel oral anti-tumor agent combining an anti-neoplastic thymidine-based nucleoside analogue (trifluridine, FTD) with a thymidine phosphorylase inhibitor (tipiracil hydrochloride, TPI) presents a new treatment option for metastatic colorectal cancer (mCRC) patients refractory or intolerant to standard therapies. 30445951

2018

Entrez Id: 7055
Gene Symbol: THAS
THAS
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE TAS-102 has led to a significant improvement in overall survival (OS) and progression-free survival (PFS) of patients with metastatic colorectal cancer (mCRC). 29970575

2018

Entrez Id: 7055
Gene Symbol: THAS
THAS
Secondary malignant neoplasm of colon and/or rectum
0.100 Biomarker BEFREE After the failure of standard treatments, regorafenib and TAS-102 would be recommended for patients with mCRC, however, they have not been approved in China during this study period. 29576426

2018